TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32916135

Group type: EXPERIMENTAL
Intervention: Biomarker strategy group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Biomarker strategy group (per-protocol population)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (per-protocol population)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study: 34935103

Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 34307140

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy group (sustained-release fluorouracil implants after standard D2 radical gastrectomy, followed by XELOX adjuvant chemotherapy)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (standard D2 radical gastrectomy, followed by XELOX adjuvant chemotherapy)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 35442534

Group type: EXPERIMENTAL
Intervention: Online teaching video and case-based discussion (CBD), n=30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional lecture-based teaching, n=30
Number of subjects: 60
Study: 34133479

Group type: EXPERIMENTAL
Intervention: Tirofiban combined with ozagrel (n=113)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Tirofiban (n=110)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Ozagrel (n=114)
Number of subjects: 337
Study: 32813899

Group type: EXPERIMENTAL
Intervention: Local excision (LE) after neoadjuvant radiochemotherapy (RCT)
Number of subjects: 110
Study: 33397287

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1.5 mg/kg bolus over 5 min followed by 1.5 mg/kg/h infusion)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 71
Study: 34708441

Group type: EXPERIMENTAL
Intervention: MINST+EMD
Number of subjects: 36

Group type: COMPARATOR
Intervention: MINST
Number of subjects: 36
Study: 33588086

Group type: EXPERIMENTAL
Intervention: Carbon fibre shoe‐stiffening inserts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham inserts
Number of subjects: 100
Study: 32000753

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (40μm)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glycine (25μm)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Erythritol (14μm)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison of all three powders
Number of subjects: 64
Study: 35060676

Group type: EXPERIMENTAL
Intervention: Experimental group in Stage I and Stage II of the adaptive two-stage design (ATD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental arm in Stage II if propensity score distributions are comparable
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized stage II if propensity score distributions are not comparable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive two-stage design (ATD)
Number of subjects: 0
Study: 35608017

Group type: EXPERIMENTAL
Intervention: Combined oral minocycline 100 mg per day plus NBUVB phototherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo plus NBUVB
Number of subjects: 14
Study: 33463408

Group type: EXPERIMENTAL
Intervention: Egalitarian gender norms and beliefs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional gender norms favoring males
Number of subjects: 0
Study: 32957220

Group type: EXPERIMENTAL
Intervention: SU‐SE (10‐MDP based universal adhesive in self‐etching mode)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SU‐ER (10‐MDP containing universal adhesive applied on etch‐and‐rinse mode)
Number of subjects: 102

Group type: COMPARATOR
Intervention: SB (two‐step etch‐and‐rinse adhesive, 10‐MDP‐free control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CHX (2% chlorhexidine digluconate aqueous solution)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups with CHX pre‐treatment
Number of subjects: 102
Study: 35698927

Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium (both dosages)
Number of subjects: 0
Study: 34753411

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 55
Study: 36157936

Group type: EXPERIMENTAL
Intervention: Postoperative platelet elevation rate on the first day (PPER1)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Postoperative platelet elevation rate on the third day (PPER3)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Generalized Linear Model (GLM)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Least Absolute Shrinkage and Selection Operator (LASSO)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Random Forest Model (RFM)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Decision Curve Analysis (DCA) and Clinical Impact Curve (CIC)
Number of subjects: 483
Study: 34247588

Group type: EXPERIMENTAL
Intervention: Nurse‐led telephonic case management
Number of subjects: 500

Group type: COMPARATOR
Intervention: Specialty, outpatient palliative care
Number of subjects: 500
Study: 33258788

Group type: EXPERIMENTAL
Intervention: LEAN intervention (mobile texting and lay health supporters)
Number of subjects: 277

Group type: COMPARATOR
Intervention: 686 Program alone (control)
Number of subjects: 277
Study: 36122268

Group type: EXPERIMENTAL
Intervention: Chronic foot pain (CFP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (without CFP)
Number of subjects: 200
Study: 32385164

Group type: EXPERIMENTAL
Intervention: ΔSUVmax approach
Number of subjects: 596

Group type: COMPARATOR
Intervention: Deauville score
Number of subjects: 596
Study: 34936196

Group type: COMPARATOR
Intervention: Reattachment followed by placement of two external vertical grooves on the labial surface and restored with polyethylene fibers and hybrid composite (Ribbond group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reattachment followed by two external vertical grooves and filled with fiber posts and composite (Fiber post group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reattachment followed by circumferential chamfer at the fracture line and restored with composite (Chamfer group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 32005012

Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATO) 20 mg daily plus dexamethasone (DXM) regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atorvastatin (ATO) 20 mg daily
Number of subjects: 60
Study: 35059244

Group type: EXPERIMENTAL
Intervention: Supervised exercise (aerobic and resistance exercise 3 times/week for 12 weeks)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 228
Study: 33059613

Group type: EXPERIMENTAL
Intervention: Prescribed drug use
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Supplemental drugs (iron folate)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category A
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category B
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category C
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category D or X
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Education level (primary education)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Education level (secondary education)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: History of chronic illness
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Multigravida status
Number of subjects: 314
Study: 32744040

Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Taopatch® devices
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Occlusal splint and Taopatch® devices together
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline (no treatments)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bite alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Taopatch® devices alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bite and Taopatch® devices used alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Functional tests (sEMG, kinesiography, squat jump, handgrip test)
Number of subjects: 18
Study: 34348347

Group type: EXPERIMENTAL
Intervention: 8-week combined endurance, resistance, and balance exercise training
Number of subjects: 30
Study: 35716850

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypoglycaemic parameters
Number of subjects: 40
Study: 34301649

Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: LASSO regression model
Number of subjects: 1177

Group type: COMPARATOR
Intervention: GWTG-HF risk score model
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 1177
Study: 34369239

Group type: EXPERIMENTAL
Intervention: Bone conduction hearing device with high maximum power output
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bone conduction hearing device with lower maximum power output
Number of subjects: 16
Study: 34932713

Group type: EXPERIMENTAL
Intervention: Type 1 cantilevers (3 bends)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Type 2 cantilevers (2 bends)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Type 1 cantilevers
Number of subjects: 80
Study: 35219309

Group type: EXPERIMENTAL
Intervention: Call for life Uganda (C4LU) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 0
Study: 32088296

Group type: EXPERIMENTAL
Intervention: Colesevelam (3 tablets, 625 mg each, orally twice daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (matching placebo, orally twice daily for 4 weeks)
Number of subjects: 30
Study: 34242140

Group type: EXPERIMENTAL
Intervention: Cuff Leak Test (CLT) communicated to healthcare team
Number of subjects: 100

Group type: COMPARATOR
Intervention: No communication of CLT results to healthcare team (control)
Number of subjects: 100
Study: 34149030

Group type: EXPERIMENTAL
Intervention: muscle sealant
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: fascia sealant
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tisseel sealant
Number of subjects: 28

Group type: COMPARATOR
Intervention: unsealed control
Number of subjects: 28
Study: 35425986

Group type: EXPERIMENTAL
Intervention: Family Centered Advance Care Planning for Teens with Cancer (FACE‐TC); 3 weekly sessions
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Family Centered Advance Care Planning for Teens with Cancer (FACE‐TC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 126
Study: 33661716

Group type: EXPERIMENTAL
Intervention: cPCV7
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control (licensed tetanus, diphtheria, and acellular pertussis vaccine)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control (23-valent polysaccharide vaccine)
Number of subjects: 511
Study: 32618958

Group type: EXPERIMENTAL
Intervention: Participants with PSCs (n = 73)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Products used to manage PSCs
Number of subjects: 153
Study: 35753838

Group type: COMPARATOR
Intervention: EV71 vaccine (separate administration)
Number of subjects: 680

Group type: COMPARATOR
Intervention: MR vaccine (separate administration)
Number of subjects: 680
Study: 34780558

Group type: EXPERIMENTAL
Intervention: On-target message (n = 73)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Off-target message (n = 98)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Overall performance of RAL
Number of subjects: 843
Study: 33356449

Group type: EXPERIMENTAL
Intervention: Targeted delivery systems based on nanoparticles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various delivery routes (oral, intradermal, intravenous)
Number of subjects: 0
Study: 34551495

Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 ml/kg (group V1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tidal volume of 5 ml/kg (group V2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tidal volume of 7 ml/kg (group V3)
Number of subjects: 180
Study: 32157435

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Not applicable (control group: placebo)
Number of subjects: 141
Study: 36142043

Group type: EXPERIMENTAL
Intervention: Healthy purchase habits (measured by AFHC purchase scores) in female adolescents declaring body mass gain during the COVID-19 pandemic
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Healthy purchase habits (measured by AFHC purchase scores) in female adolescents declaring physical activity decrease during the COVID-19 pandemic
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Healthy consumption habits (measured by AFHC consumption scores) in male adolescents declaring physical activity increase during the COVID-19 pandemic
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: General food habits
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Body mass changes associated with food habits during the COVID-19 pandemic
Number of subjects: 1333
Study: 34860040

Group type: EXPERIMENTAL
Intervention: Randomized measurement protocols combined with importance sampling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classical techniques of machine learning and tensor networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimation of purity of product states and GHZ states
Number of subjects: 0
Study: 35708779

Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel technique (MCAT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGG)
Number of subjects: 50
Study: 35140163

Group type: EXPERIMENTAL
Intervention: Combined online mindfulness-based stress reduction (MBSR) and exercise programme (MOVE-Online), 2 hours MBSR and 1 hour exercise once a week for 8 weeks.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Online self-management guide, released biweekly with eight self-directed modules over 8 weeks.
Number of subjects: 75
Study: 32189663

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine 0.2 µg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 0.4 µg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous normal saline 10 mL (placebo)
Number of subjects: 120
Study: 36442169

Group type: EXPERIMENTAL
Intervention: Online supervised exercise program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 35288477

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg subcutaneous dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 32887990

Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 0
Study: 32276019

Group type: EXPERIMENTAL
Intervention: Digital fluoroscopy (DF)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 43
Study: 34210600

Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lullabies
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study: 33258354

Group type: EXPERIMENTAL
Intervention: Flesh-moistening paste applied topically twice daily for eight weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo applied topically twice daily for eight weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flesh-moistening paste
Number of subjects: 50
Study: 35220432

Group type: EXPERIMENTAL
Intervention: Management based on HyFoSy
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Management based on HSG
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: HyFoSy
Number of subjects: 1026

Group type: COMPARATOR
Intervention: HSG
Number of subjects: 1026
Study: 34330462

Group type: EXPERIMENTAL
Intervention: REPLENISH group (target protein 1.8-2.2 g/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard group (target protein 0.8-1.0 g/kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anthropometric and muscle strength measurements
Number of subjects: 40
Study: 35643253

Group type: EXPERIMENTAL
Intervention: SABR to all metastases plus standard of care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Palliative standard-of-care treatment
Number of subjects: 99
Study: 32409439

Group type: EXPERIMENTAL
Intervention: IL-6 inhibitors
Number of subjects: 0
Study: 33111455

Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥ 25–29.9 kg m−2)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg m−2)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Combined overweight and obesity
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Married women
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Women aged 30–49 years
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Unemployed women
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Women from wealthier households
Number of subjects: 525
Study: 33275769

Group type: EXPERIMENTAL
Intervention: Short-term maintenance rituximab (375 mg/m2 every 2 months, 4 administrations; n = 82)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Long-term maintenance rituximab (375 mg/m2 every 2 months, up to 5 years; n = 83)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Short-term maintenance rituximab
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Long-term maintenance rituximab
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Symptomatic patients in need of immediate treatment
Number of subjects: 270
Study: 33773059

Group type: EXPERIMENTAL
Intervention: Smart Glove (50 minutes per day, 5 days per week for 8 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smart Glove
Number of subjects: 20
Study: 34215241

Group type: EXPERIMENTAL
Intervention: Chinese version of the entrapment scale (ES)
Number of subjects: 304
Study: 36269726

Group type: EXPERIMENTAL
Intervention: Normal previous cervical smear (Group 1)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: High-grade cervical dysplasia (H-SIL) at previous cervical smear (Group 2)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HIV-positive women (Group 3)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 360
Study: 33637548

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Conventional placebo (CP)
Number of subjects: 267

Group type: COMPARATOR
Intervention: No treatment (observational control)
Number of subjects: 267
Study: 35452194

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Moderate/severe depression (HDRS ≥ 17)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Mild depression (8 ≤ HDRS ≤ 16)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Remission at week 4
Number of subjects: 570
Study: 34078103

Group type: COMPARATOR
Intervention: No WML
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Mild WML
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Moderate to Severe WML
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: Increasing WML grades
Number of subjects: 3180
Study: 36317847

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) implant
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) implant
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medial-stabilized (MS) implant
Number of subjects: 75
Study: 32851588

Group type: EXPERIMENTAL
Intervention: Sleep efficiency less than 85%
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Nocturnal awakening
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Getting up to use the bathroom
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Use of sleep medication
Number of subjects: 1308
Study: 33079965

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 36333935

Group type: EXPERIMENTAL
Intervention: Digital health app video consultations
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional face-to-face consultations
Number of subjects: 52
Study: 34293372

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional formula (Control)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: EHF
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study: 33141833

Group type: EXPERIMENTAL
Intervention: Phone calls
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Text messages (SMS)
Number of subjects: 1542

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 1542
Study: 33684639

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise program (CSEP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Physical activity counseling
Number of subjects: 21
Study: 32658428

Group type: EXPERIMENTAL
Intervention: AK124776 in recurrent group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RP11-160A10.2 in recurrent group
Number of subjects: 60

Group type: COMPARATOR
Intervention: AK124776
Number of subjects: 60

Group type: COMPARATOR
Intervention: RP11-160A10.2
Number of subjects: 60